EPM
KROS icon

Equitec Proprietary Markets’s Keros Therapeutics KROS Stock Holding History

Equitec Proprietary Markets’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,600
Closed -$175K – 99
2025
Q4 		$175K Buy
+8,600
New +$151K 0.1% 35

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Equitec Proprietary Markets's KROS Position: Q1 2026 in Review

Equitec Proprietary Markets sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 8,600 shares — an estimated $175K sold.

Equitec Proprietary Markets first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $175K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Equitec Proprietary Markets reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Equitec Proprietary Markets sold 8,600 Keros Therapeutics shares in Q1 2026, an estimated $175K.
  • Equitec Proprietary Markets first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
  • Equitec Proprietary Markets's Keros Therapeutics position peaked at $175K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Equitec Proprietary Markets's 13F filing for Q1 2026, filed 11 May 2026.